SUBSCRIBE
SUBSCRIBE

Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

  • 2025 BPTW Badge - RBG.png
  • 2024 - Best Places to Work - Badges - Brighspot Rework - Outlined - 20pt.png
211 Mt. Airy Road
Basking Ridge, NJ 07920
Tel: (908) 992-6400
Visit website
  • Featured Employer
NEWS
Business
AstraZeneca and Daiichi Sankyo Ink $6 Billion Cancer Pact
AstraZeneca inked a global development and commercialization deal with Daiichi Sankyo Company for DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) for multiple cancer types.
July 27, 2020
 · 
3 min read
 · 
Mark Terry
Business
Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device for NSCLC
The diagnostic tool will use Thermo Fisher’s next-generation sequencing (NGS)-based Oncomine Dx Target Test to identify HER2 (human epidermal growth factor receptor 2) gene mutations.
June 23, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: June 12
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
June 11, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Business
Daiichi Sankyo, Syneos Health Eye New Cancer Therapies with Collaboration Agreement
Daiichi Sankyo announced on May 28 that it had entered an agreement with Syneos Health to form a coalition dedicated to bringing new cancer therapies to patients in a safe and effective manner.
June 5, 2020
 · 
3 min read
 · 
Krystle Vermes
Policy
Seattle Genetics Claims Arbitration Rights in Daiichi Sankyo ADC Dispute
In a filing with the court, Seattle Genetics claimed the right to arbitration to resolve the dispute with Daiichi Sankyo, as is required by the 2008 collaboration agreement.
December 3, 2019
 · 
2 min read
 · 
Alex Keown
Policy
Daiichi Sankyo and Seattle Genetics are Headed to Court Over an ADC Worth Billions
Daiichi Sankyo is taking Seattle Genetics to court over the technology the two companies used to develop antibody-drug conjugates during a partnership that spanned seven years.
November 6, 2019
 · 
2 min read
 · 
Alex Keown
Genetown
New Pharma Invention Index Picks AstraZeneca as Top Company
The newly-launched index takes a focused look at the breadth and depth of novel agents currently being developed within the most innovative pharmaceutical pipelines.
November 5, 2019
 · 
3 min read
 · 
Alex Keown
BioCapital
Clinical Catch-Up: September 2-8
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
September 6, 2019
 · 
11 min read
 · 
Mark Terry
Daiichi Sankyo Reports Non-Inferiority in Lixiana Clinical Trial for Atrial Fibrillation
The company indicates there was “a trend toward less bleeding with edoxaban, though, results did not show statistical superiority.”
September 4, 2019
 · 
2 min read
 · 
Mark Terry
Load More
JOBS
View All Jobs at Daiichi Sankyo
IN THE PRESS
Pharm Country
Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer
August 9, 2022
 · 
11 min read
Drug Development
HERTHENA-Lung02 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
August 8, 2022
 · 
6 min read
Job Trends
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
August 5, 2022
 · 
29 min read
FDA
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
August 5, 2022
 · 
29 min read
Business
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
July 25, 2022
 · 
26 min read
Policy
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast Cancer
July 25, 2022
 · 
23 min read
Drug Development
DS-7300 Phase 2 Trial Initiated in Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
July 20, 2022
 · 
5 min read
Drug Development
TROPION-Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer
June 13, 2022
 · 
6 min read
Pharm Country
Quizartinib Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy in Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
June 11, 2022
 · 
9 min read
Drug Development
DS-6000 Suggests Early Clinical Activity in Patients with Advanced Ovarian Cancer or Renal Cell Carcinoma
June 7, 2022
 · 
10 min read
Load More